EPS Corporation

EPS Group is a Japan-headquartered healthcare solutions group and one of Japan’s established development partners. Since launching its CRO business in 1991, EPS has built broad capabilities across clinical development, site support, post-marketing, pharmacovigilance, medical information, data management, biostatistics, regulatory consultation, and commercialization-related services.

For biotech companies considering Japan, EPS serves as a practical gateway to Japan and the wider Asia-Pacific region. EPS combines deep knowledge of Japan’s regulatory and clinical development environment with operational scale, nationwide site relationships, and regional experience in China, South Korea, Taiwan, and other APAC markets through its group network and partners.

In 2026, EPS launched EPS BIOPath, an integrated consulting service for biotech companies seeking to enter or optimize development in Japan. EPS BIOPath supports sponsors from early Japan-entry assessment and development strategy through regulatory consultation, clinical trial planning, execution readiness, and downstream business considerations. The service helps clarify Japan-specific requirements, leverage existing global data, reduce avoidable burden, and bridge strategy with implementation.

At EU-Japan Biotech Partnering, EPS welcomes discussions with biotech companies evaluating Japan or APAC as part of their development, regulatory, partnering, or commercialization strategy. EPS can discuss fit-for-purpose entry options including Japan participation in global trials, local feasibility, KOL and site engagement, post-marketing planning, safety operations, and partner coordination.